Towards Healthcare Research & Consulting

Brazil Non-invasive Brain Stimulation System Market Size, Share, Forecast (2026-2035), TMS, tDCS and Other Neuromodulation Systems for Depression, Pain, OCD and Neurology

The Brazil non-invasive brain stimulation system market is estimated at USD 41.72 million in 2026 and is projected to reach USD 96.78 million by 2035, expanding at a CAGR of 9.80% from 2026 to 2035. It was valued at USD 38.00 million in the base year 2025. The Brazil non-invasive brain stimulation system market covers devices used for non-invasive brain stimulation, including transcranial magnetic stimulation (TMS) systems, transcranial direct current stimulation (tDCS) devices, and other neuromodulation technologies. These systems are used to treat major depression, chronic pain and fibromyalgia, obsessive-compulsive disorder, stroke-related conditions, and other neurological disorders. Key end-use settings include hospitals, psychiatric and neurology clinics, rehabilitation centers, and research institutes. Transcranial Magnetic Stimulation (TMS) accounted for the largest technology share in 2025, at 64.00%, because Brazil's Federal Council of Medicine recognizes it for depression and other indications. Southeast accounted for 54.00% of revenue in 2025, supported by most private clinics and research centers in São Paulo, Rio de Janeiro, and Minas Gerais. Demand is driven by depression burden, treatment resistance, clinic growth and professional guidance. Practice standards are being clarified, with SBNC's February 2026 position on TMS and tDCS indications.

Last updated 20 November 2026   |   Primary source: Towards Healthcare   |   Report: 7219   |   Derived values are labelled
USD 41.72 Mn
Revenue, 2026
USD 96.78 Mn
Forecast, 2035
9.80%
CAGR, 2026-2035
Brazil
Report Coverage

Key Takeaways

Brazil Non-invasive Brain Stimulation System Market Snapshot, Comparison and Top Companies

Market Size & Growth Outlook

  • Market size in 2025: USD 38.00 million
  • Estimated market size in 2026: USD 41.72 million
  • Projected market size by 2035: USD 96.78 million
  • CAGR (2026-2035): 9.80%

Regional Market Spotlight

  • Southeast led the market with a 54.00% share in 2025.
  • South held an 18.00% share of the market in 2025.
  • Northeast represented 14.00% of the market in 2025 and is projected to be the fastest-growing region, with a CAGR of 11.04% from 2026 to 2035.

Segmental Spotlight

  • Transcranial Magnetic Stimulation (TMS) emerged as the leading technology in 2025, capturing a 64.00% market share.
  • Depression dominated the application segment, representing 50.00% of the market in 2025.
  • Psychiatric & Neurology Clinics led the end-user segment with a 56.00% market share in 2025.

The Brazil non-invasive brain stimulation system market is forecast to expand from USD 38.00 million in 2025 to USD 96.78 million by 2035, registering a CAGR of 9.80% throughout the forecast timeframe. Rising depression prevalence and increasing treatment resistance are driving demand for drug-free alternatives such as TMS and tDCS. Expanding clinics, professional guidance, and growing adoption of advanced psychiatric treatments further support market growth, with revenue expected to reach USD 60.65 million by 2030. Integration of brain stimulation with telehealth follow-ups and precision medicine approaches is also supporting market development.

Brazil Non-invasive Brain Stimulation System Market Size is USD 41.72 Million in 2026.

Analyst View: We built the estimate from installed TMS and tDCS devices, new placements and average device prices by region in Brazil, cross-checked against supplier activity. Published estimates for this scope are limited, so our value is evidence-based.

  • Growing clinical evidence supporting TMS and tDCS for depression and other neurological conditions is strengthening adoption across Brazil.
  • Increasing interest in supervised home-based tDCS is expanding access to non-invasive brain stimulation beyond clinical settings.
  • Adoption of shorter, intensive TMS treatment protocols is improving patient convenience and clinic treatment capacity.
  • Growing emphasis on clinician training and certification is supporting safe and standardized neuromodulation practices.
  • Broader private insurance reimbursement could improve patient access and encourage wider adoption of brain stimulation systems.
  • Evaluation of non-invasive brain stimulation within Brazil's public SUS healthcare system could create opportunities for wider institutional adoption.

Drivers, Restraints and Opportunities

Market Drivers - Impact & CAGR Contribution (2026-2035)

Driver Impact ≈ CAGR Contribution Time Horizon Key Regions
High depression burden High +3.83 pp Short to long term All covered regions, strongest in Southeast
Treatment-resistant patients Medium +3.23 pp Medium to long term All covered regions, fastest uptake in Northeast
Growing clinics Medium +2.75 pp Short to medium term All covered regions
Professional guidelines Low +2.15 pp Long term Southeast and Northeast

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Taken together, these drivers add about 11.96 percentage points to the annual growth of the Brazil non-invasive brain stimulation system market, with high depression burden having the largest effect. Their influence is strongest in Southeast, while uptake grows fastest in Northeast.

Market Restraints - Impact & Negative CAGR Contribution (2026-2035)

Restraint Impact ≈ Negative CAGR Contribution Time Horizon Key Regions
Limited insurance coverage High -0.97 pp Short to medium term All covered regions
Device import costs High -0.71 pp Medium term Smaller and price-sensitive markets
Regulatory gaps for tDCS Medium -0.47 pp Short term Southeast and other mature markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

These restraints are expected to reduce annual growth of the Brazil non-invasive brain stimulation system market by about 2.16 percentage points, led by limited insurance coverage. Their effect eases over the forecast period as suppliers, buyers and regulators adapt, leaving a net CAGR of 9.80% from 2026 to 2035.

Market Opportunity

Accelerated TMS protocols offer opportunities to improve treatment efficiency and increase clinic capacity. Expanding healthcare infrastructure in Northeast Brazil, growing interest in supervised home-based tDCS, and increasing adoption across pain clinics can widen the addressable market. Potential inclusion of brain stimulation therapies in Brazil's public SUS healthcare system could further improve accessibility and institutional demand.

Market Segmentation: 2025 Share and Value

Brazil Non-invasive Brain Stimulation System Market by Technology 2025 Share

Brazil Non-invasive Brain Stimulation System Market, By Technology, Segment Dominates by 64% in 2025.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Transcranial Magnetic Stimulation (TMS) segment accounted for 64.00% of the Brazil non-invasive brain stimulation system market in 2025 and is projected to expand at a CAGR of 9.05% from 2026 to 2035. TMS leads because Brazil's Federal Council of Medicine recognises it for depression and other indications. The transcranial magnetic stimulation (tms) segment is expected to grow slower than the overall market over the forecast period.

Transcranial Direct Current Stimulation (tDCS) expansion is driven by the relatively low cost, portability, and accessibility of tDCS devices. The segment is expected to outperform the overall market.

Others demand is supported by emerging neuromodulation technologies and newer brain stimulation methods. However, growth is projected to remain slower than the overall market.

Brazil Non-invasive Brain Stimulation System Market by Application 2025 Share

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Depression: Leading the application segment with a 50.00% market share in 2025, this segment is projected to grow at a CAGR of 10.10% from 2026 to 2035. Its dominance reflects the strong clinical evidence supporting TMS and tDCS for major depression. Growth is expected to remain broadly in line with the overall market.

Chronic Pain & Fibromyalgia growing use of TMS for chronic pain management and fibromyalgia treatment supports demand. However, growth is expected to remain below the overall market rate.

OCD & Addiction increasing use of TMS in obsessive-compulsive disorder and nicotine dependence treatment supports adoption, although growth is expected to remain slower than the overall market.

Stroke Rehabilitation & Others demand from stroke rehabilitation and other neurological applications contributes to segment development. Nevertheless, growth is projected to remain below the overall market rate.

Brazil Non-invasive Brain Stimulation System Market by End User 2025 Share

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Psychiatric & Neurology Clinics: Dominating the end-user segment with a 56.00% market share in 2025, this category is projected to grow at a CAGR of 10.06% from 2026 to 2035. Its leading position reflects the widespread delivery of TMS treatments through outpatient psychiatric and neurology clinics. Growth is expected to remain broadly in line with the overall market.

Hospitals use stimulation in psychiatry units. The hospitals segment is expected to grow slower than the overall market over the forecast period.

Research & Rehabilitation Centres demand is supported by growing research activities and the use of neuromodulation technologies in rehabilitation settings. Growth is expected to remain slower than the overall market.

Analyst View: Market shares across individual segments were estimated using category-wise demand, product offerings, and pricing patterns. TMS, Depression, and Psychiatric & Neurology Clinics maintain leading positions due to their established clinical applications and alignment with current treatment requirements. Meanwhile, tDCS is expected to gain market share as adoption expands across emerging technologies, patient groups, and therapeutic applications.

Regional Analysis

Brazil Non-invasive Brain Stimulation System Market by Region 2025 Share

Region 2025 Share 2035 Share CAGR 2026-2035
Southeast 54.00% 52.23% 9.44%
South 18.00% 18.06% 9.84%
Northeast 14.00% 15.65% 11.04%
Central-West 9.00% 9.03% 9.84%
North 5.00% 5.02% 9.84%

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources,Towards Healthcare database and Towards Healthcare analysts.

Southeast: Dominating the regional market with a 54.00% share in 2025, the Southeast is projected to grow at a CAGR of 9.44% throughout the forecast period. São Paulo, Rio de Janeiro, and Minas Gerais drive regional demand through their concentration of private clinics and research centers. However, growth is expected to remain below the overall market rate.

South: This region accounted for 18.00% of the Brazil non-invasive brain stimulation system market in 2025 and is projected to expand at a CAGR of 9.84% from 2026 to 2035. The South has strong private health systems. South is expected to grow broadly in line with the overall market between 2026 and 2035.

Northeast: Holding a 14.00% market share in 2025, the Northeast is expected to register the fastest regional growth, with a CAGR of 11.04% from 2026 to 2035. Expanding clinics and healthcare infrastructure in Recife, Salvador, and Fortaleza are driving market development. The region is projected to outperform the overall market.

Central-West: This region accounted for 9.00% of the Brazil non-invasive brain stimulation system market in 2025 and is projected to expand at a CAGR of 9.84% throughout the forecast timeframe. Central-West includes Brasília. Central-West is expected to grow broadly in line with the overall market between 2026 and 2035.

North: Representing the smallest regional share at 5.00% in 2025, the North is forecast to grow at a CAGR of 9.84% from 2026 to 2035. Limited access to specialized healthcare facilities and neuromodulation services constrains regional adoption. Growth is expected to remain broadly in line with the overall market.

Analyst View: Regional market shares were estimated based on demand patterns, installed equipment, healthcare spending, and supplier presence across Brazil's key regions. The Southeast maintains its leading position due to its established healthcare infrastructure, mature demand, and strong supplier network. Meanwhile, the Northeast receives the highest growth premium, supported by rising investments, increasing adoption, and expanding treatment capacity.

Competitive Landscape

Top 10 Companies in the Brazil Non-invasive Brain Stimulation System Market, 2025

Brazil Non-invasive Brain Stimulation System Market Companies are MagVenture, Magstim, Neurosoft, Soterix Medical, Neuronetics, BrainsWay, Neuroelectrics, Neuroconn (neurocare), Flow Neuroscience, Deymed Diagnostic

Rank Company Name 2025 Share (%) Key Products / Business Headquarters
1 MagVenture 18.00% TMS systems Denmark
2 Magstim 16.00% TMS systems United Kingdom
3 Neurosoft 10.00% Neuro-MS TMS Russia
4 Soterix Medical 8.00% tDCS devices United States
5 Neuronetics 6.00% NeuroStar TMS United States
6 BrainsWay 5.00% Deep TMS Israel
7 Neuroelectrics 4.00% Starstim tDCS Spain
8 Neuroconn (neurocare) 4.00% tDCS devices Germany
9 Flow Neuroscience 3.00% Home tDCS Sweden
10 Deymed Diagnostic 3.00% TMS systems Czech Republic

Note: Company shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

MagVenture led the Brazil non-invasive brain stimulation system market with an estimated 18.00% share of 2025 revenue, followed by Magstim at 16.00% share and Neurosoft at 10.00% share. MagVenture leads with TMS systems, Magstim competes with TMS systems, and Neurosoft offers neuro-MS TMS. Soterix Medical, Neuronetics, BrainsWay, Neuroelectrics, Neuroconn (neurocare), Flow Neuroscience and Deymed Diagnostic compete through tDCS devices, neuroStar TMS, deep TMS, starstim tDCS, tDCS devices, home tDCS, and TMS systems.

The top 10 companies accounted for an estimated 77.00% of 2025 revenue, while the remaining 23.00% was shared among local distributors and clinics. The Brazil non-invasive brain stimulation system market is fragmented, and competition centers on ANVISA registration, clinical evidence, local distribution and service, training support and price.

Company Snapshots

MagVenture: Based in Denmark, MagVenture held an 18.00% share of the Brazil non-invasive brain stimulation system market in 2025. Its product portfolio focuses on TMS systems for clinical applications. The company occupies a Leader position in the Towards Healthcare Companies Quadrant.

Magstim: The United Kingdom-based company captured approximately 16.00% of the Brazilian market in 2025. Its offerings centre on TMS systems used in neurological and psychiatric treatments. Magstim is classified as a Leader in the Towards Healthcare Companies Quadrant.

Neurosoft: Headquartered in Russia, Neurosoft represented 10.00% market share in 2025. Its portfolio includes Neuro-MS TMS systems for non-invasive brain stimulation. The company is positioned as a Leader in the Towards Healthcare Companies Quadrant.

Soterix Medical: Operating from the United States, Soterix Medical secured approximately 8.00% of the market in 2025. Its product range focuses on tDCS devices for neuromodulation applications. The company holds a Leader position in the Towards Healthcare Companies Quadrant.

Neuronetics: With its headquarters in the United States, Neuronetics accounted for a 6.00% market share in 2025. Its portfolio features NeuroStar TMS systems for depression treatment. The company is recognised as a Leader in the Towards Healthcare Companies Quadrant.

BrainsWay: Based in Israel, BrainsWay captured approximately 5.00% of the Brazilian market in 2025. Its offerings focus on Deep TMS technology for psychiatric and neurological applications. The company is positioned as a Leader in the Towards Healthcare Companies Quadrant.

Neuroelectrics: The Spain-based company held a 4.00% market share in 2025. Its portfolio includes Starstim tDCS systems for advanced brain stimulation applications. Neuroelectrics occupies an Innovator position in the Towards Healthcare Companies Quadrant.

Neuroconn (neurocare): Headquartered in Germany, Neuroconn (neurocare) represented approximately 4.00% of the market in 2025. Its product offerings focus on tDCS devices for non-invasive neuromodulation. The company is classified as an Innovator in the Towards Healthcare Companies Quadrant.

Flow Neuroscience: Operating from Sweden, Flow Neuroscience accounted for 3.00% market share in 2025. Its portfolio centres on home-based tDCS systems designed to support supervised treatment outside clinical settings. The company holds an Innovator position in the Towards Healthcare Companies Quadrant.

Deymed Diagnostic: Based in the Czech Republic, Deymed Diagnostic captured approximately 3.00% of the Brazilian market in 2025. Its product range includes TMS systems for clinical and research applications. The company is positioned as an Innovator in the Towards Healthcare Companies Quadrant.

Companies Ecosystem

The Brazil non-invasive brain stimulation system ecosystem links device makers, distributors, clinics & hospitals, professional societies and regulators & payers, with each stage adding value before products reach end users.

Ecosystem Stage Role in the Market Key Companies
Device Makers Make TMS and tDCS devices MagVenture, Magstim, Neurosoft, Soterix
Distributors Import and service devices Brazilian distributors
Clinics & Hospitals Treat patients Psychiatry and neurology clinics
Professional Societies Set practice standards SBNC, SBNM, CFM
Regulators & Payers Register devices and pay ANVISA, ANS, SUS

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Device Makers: Make TMS and tDCS devices. Key participants include MagVenture, Magstim, Neurosoft, Soterix.

Distributors: Import and service devices. Key participants include Brazilian distributors.

Clinics & Hospitals: Treat patients. Key participants include Psychiatry and neurology clinics.

Professional Societies: Set practice standards. Key participants include SBNC, SBNM, CFM.

Regulators & Payers: Register devices and pay. Key participants include ANVISA, ANS, SUS.

Value in the Brazil non-invasive brain stimulation system market flows from upstream material and technology suppliers to manufacturers and service providers, then through distribution partners to end users. Companies that integrate several stages or build long-term relationships with end users capture a larger share of this value.

Towards Healthcare Companies Quadrant

The Towards Healthcare Companies Quadrant evaluates key players in Brazil's non-invasive brain stimulation system market based on market strength and innovation capabilities. Market strength considers revenue scale, market share, and geographic presence, while innovation and growth strategies assess product portfolio diversity, R&D investments, and strategic partnerships. Company positioning is determined by estimated 2025 market shares and an evaluation of product innovation, portfolio breadth, and collaborative initiatives.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Leaders: MagVenture, Magstim, Neurosoft, Soterix Medical, Neuronetics and BrainsWay combine high market share with broad portfolios and strong innovation.

Innovators: Neuroelectrics, Neuroconn (neurocare), Flow Neuroscience and Deymed Diagnostic bring newer technologies and specialized products.

Recent Developments

  • February 2026: The Brazilian Society of Clinical Neurophysiology, endorsed by the Brazilian Society of Neuromodulation, issued a position on TMS and tDCS, recommending evidence-based indications such as depression, chronic neuropathic pain and OCD and use of ANVISA-registered devices only.

Market Segments

By Technology

  • Transcranial Magnetic Stimulation (TMS)
  • Transcranial Direct Current Stimulation (tDCS)
  • Others

By Application

  • Depression
  • Chronic Pain & Fibromyalgia
  • OCD & Addiction
  • Stroke Rehabilitation & Others

By End User

  • Psychiatric & Neurology Clinics
  • Hospitals
  • Research & Rehabilitation Centres

By Region

  • Southeast
  • South
  • Northeast
  • Central-West
  • North

Research Methodology

The Brazil non-invasive brain stimulation system market was defined as non-invasive brain stimulation systems used in Brazil, including transcranial magnetic stimulation (TMS) systems, transcranial direct current stimulation (tDCS) devices, and other neuromodulation devices, used for major depression, chronic pain and fibromyalgia, obsessive-compulsive disorder, stroke rehabilitation and other conditions in hospitals, psychiatric and neurology clinics, rehabilitation centers and research institutes. The 2025 base-year estimate was developed using a bottom-up approach, combining demand volumes and average prices across technology, application, end-user, and regional segments. The resulting market value was then cross-checked using a top-down approach against market-specific revenues of leading companies and published industry estimates.

Segment, regional and company values were allocated from technology, application and end user and region demand. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.

Analyst View: the Brazil non-invasive brain stimulation system market is set for steady expansion as depression burden and related demand keep growing. Our estimate links value to underlying demand, installed base and pricing, so the forecast follows real adoption rather than headline hype. The main upside comes from accelerated protocols and home tDCS, while the main risks are limited insurance coverage and import costs.

References

Meet the Team

Payal Rabde

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde
Aditi Shivarkar

Aditi Shivarkar LinkedIn

Reviewed By

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar